Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by hmmmmmmmmon Feb 01, 2023 4:26pm
164 Views
Post# 35260653

RE:A triple and a double...

RE:A triple and a double...Marketing is easy when you have something to market.

When like CTSO you are enrolling 40 patients per quarter- people can get excited, and people can clearly see an end date where their investment should pay off.

When you enroll 3 or 4 patients a quarter- you have nothing to "market".

It all comes back to a management team that can deliver professional results.

Easy to find many examples of companies currently conducting trials in a normal, timely mannor.
<< Previous
Bullboard Posts
Next >>